Age-Related Decline in a Cellular Recycling Pathway Lets 'Zombie' Cells Pile Up, Mouse Study Finds

The work, published in Nature Aging in 2026, comes from a group at Albert Einstein College of Medicine. It is preclinical research. The study describes experiments in cells grown in the lab and in mice, including a mouse model of lung scarring. It does not report a human trial.

Senescent cells have stopped dividing but stay alive. They release inflammatory signals, known as the senescence-associated secretory phenotype. Some senescent cells help with jobs like wound healing. Their persistence in older tissue is linked to age-related disease.

The study focuses on chaperone-mediated autophagy, or CMA. It is a pathway that picks out specific proteins and breaks them down inside the cell's recycling compartments, called lysosomes. A separate 2025 Nature Aging study from the same research group, using reporter mice, found that CMA activity falls with age in most organs and cell types, and that the fall was greater in males.

The loss of CMA changes how senescent cells behave. Cells lacking CMA still became senescent, but they took on features resembling those of senescent cells from aged animals. Their secretions pushed neighboring cells toward senescence more strongly. Those secretions also reduced CMA in macrophages, the immune cells that engulf senescent cells. With less CMA, the macrophages were worse at engulfing them.

The mouse experiments point the same way. Blocking CMA only in macrophages increased the number of senescent cells in mice. It also delayed the resolution of senescence during wound healing. In the other direction, a drug that activates CMA reduced senescent cell burden in aged mice. It also reduced disease severity in the pulmonary fibrosis model. The authors write that CMA decline is a driver of senescent cell persistence.

Lifespan.io reports that the compound was called CA77.1. It reports that treatment started two days after lung injury reduced fibrosis, while treatment started on day 7 did not. It also reports that effects in aged mice varied by tissue, sex and marker, and that lung tissue from people with fibrosis showed reduced CMA function. We could not check these points against the full paper.

Why does this matter for healthy aging? If the answer holds up, clearing senescent cells may depend partly on keeping the immune system's own recycling machinery working. That would offer a different target from drugs that kill senescent cells directly. If it does not hold up, senescent cells may build up for other reasons, and boosting CMA would not help much. The weakest point is that the evidence is from mice and lab-grown cells.

For now, this is not advice for daily life. CA77.1 is described by Lifespan.io as a drug known to activate CMA, and it has not been shown to be safe or effective in people. Lifespan.io quotes study leader Ana Maria Cuervo: "By restoring cellular recycling, we may be able to help the body's own defenses clear these cells more effectively. The next challenge is determining whether this approach can eventually be developed into a safe treatment for age-related diseases in people."

What to watch next

Whether the findings are reproduced, whether the full data show consistent effects across sexes and tissues, and whether any CMA-activating drug moves into safety testing in people.

1. Age-Related Decline in a Cellular Recycling Pathway Lets 'Zombie' Cells Pile Up, Mouse Study Finds 2. Large Review Links Insomnia to 26% Higher Stroke Risk and More Hospital Stays 3. Large Trial Finds Test Scores Rose in All Groups of Older Adults With Low Cognitive Scores, With Slightly More Gain From a Website and Brief Support 4. Testosterone Therapy Linked to Higher Cardiovascular Risk in Postmenopausal Women 5. Report: White House Stalls Kennedy's Push for a Federal Definition of Ultra-Processed Food